Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | TEK | Q02763 | 1/20 | 0.51 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.51 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487003 | 0.89 | MEN1 (0.61) | SCN9AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL12262446 | 0.85 | SCN9A (0.64) | SCN9AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3431925 | 0.85 | CDK1 (0.60) | SCN9AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL691344 | 0.84 | MEN1 (0.59) | SCN9AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14769593 | 0.84 | SCN9A (0.56) | SCN9AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL9929561 | 0.84 | SCN9A (0.56) | SCN9AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2174012 | 0.83 | SCN9A (0.61) | SCN9AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3487000 | 0.82 | MEN1 (0.64) | SCN9AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL1095089 | 0.81 | MEN1 (0.52) | SCN9AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL10187337 | 0.81 | MEN1 (0.81) | SCN9AMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | SCN9A 4436/4885MEN1 3993/4885KMT2A 1280/4885 |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | SCN9A 4436/4885MEN1 3993/4885KMT2A 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.